spread
rapidli
europ
north
america
specif
tool
control
grow
epidem
treat
sick
reli
quarantin
isol
infectioncontrol
measur
prevent
diseas
spread
support
care
becom
ill
lack
specif
antivir
agent
treat
infect
optim
decreas
viral
shed
subsequ
transmiss
one
antiviraldrug
candid
combin
hiv
proteas
inhibitor
lopinavir
ritonavir
lopinavir
act
viral
proteas
modest
antivir
activ
togeth
ritonavir
increas
drug
bioavail
clinic
trial
along
immunomodul
interferon
treatment
middl
east
respiratori
syndrom
mer
clinicaltrialsgov
number
make
lopinavirritonavir
particularli
attract
wide
avail
manufactur
scale
could
prescrib
immedi
fact
sever
case
report
case
seri
agent
use
work
question
motiv
cao
colleagu
perform
urgent
random
clinic
trial
efficaci
lopinavirritonavir
patient
wuhan
china
epicent
outbreak
januari
first
patient
enrol
openlabel
trial
week
identifi
sequenc
investig
recruit
patient
oxygen
satur
less
breath
ambient
air
ratio
partial
pressur
oxygen
fraction
inspir
oxygen
less
mm
hg
receiv
rang
ventilatori
support
mode
noth
mechan
ventil
extracorpor
membran
oxygen
ecmo
enrol
stratifi
accord
sever
ill
indic
level
ventilatori
support
administ
patient
receiv
standard
care
half
randomli
assign
receiv
lopinavirritonavir
day
primari
end
point
time
clinic
improv
defin
time
random
either
discharg
hospit
improv
multifactori
set
prespecifi
criteria
whichev
came
first
trial
aim
enrol
patient
heroic
effort
health
care
worker
hubei
provinc
provid
patient
care
overwhelm
epidem
one
highest
risk
group
develop
diseas
saw
ebola
outbreak
west
africa
obtain
highqual
clinic
trial
data
guid
care
patient
extrem
difficult
face
epidem
feasibl
random
design
call
question
yet
cao
group
determin
investig
succeed
end
enrol
larger
number
patient
origin
target
unfortun
trial
result
disappoint
benefit
observ
primari
end
point
time
clinic
improv
group
requir
median
day
result
certain
secondari
end
point
intrigu
slightli
lower
number
death
seen
lopinavirritonavir
group
although
observ
difficult
interpret
given
small
number
fact
standardcar
group
appear
sicker
baselin
remov
death
lopinavirritonavir
group
occur
random
first
dose
drug
given
would
provid
encourag
result
chang
debat
sinc
remov
occur
control
group
hand
trial
openlabel
one
sinc
end
point
evalu
influenc
clinician
awar
treatment
assign
suscept
potenti
bia
import
note
group
heterogen
receiv
variou
addit
treatment
includ
pharmacolog
intervent
interferon
glucocorticoid
secondari
end
point
provid
reason
hope
reason
discourag
number
death
somewhat
lower
group
receiv
lopinavirritonavir
tellingli
though
discern
effect
viral
shed
sinc
drug
suppos
act
direct
inhibitor
viral
replic
inabl
suppress
viral
load
persist
detect
viral
nucleic
acid
strongli
suggest
activ
desir
thu
although
effect
drug
possibl
easili
observ
nt
lopinavirritonavir
effect
two
major
factor
may
play
first
author
chose
particularli
challeng
popul
patient
recruit
studi
late
infect
alreadi
consider
tissu
damag
evidenc
compromis
lung
function
mortal
control
group
even
highli
activ
antibacteri
agent
limit
efficaci
advanc
bacteri
pneumonia
second
lopinavir
simpli
nt
particularli
potent
concentr
necessari
inhibit
viral
replic
rel
high
compar
serum
level
found
patient
treat
lopinavirritonavir
current
know
littl
drug
concentr
tissu
replic
fact
trial
began
within
day
viru
identifi
test
infect
develop
deploy
rapidli
mean
test
characterist
fulli
defin
notabl
screen
posit
nasopharyng
swab
test
neg
day
visit
oropharyng
swab
due
differ
site
assess
time
ill
test
characterist
natur
evolut
diseas
addit
patient
viral
loadposit
day
quantit
data
point
show
level
low
probabl
near
threshold
detect
sinc
test
detect
nucleic
acid
posit
result
necessarili
indic
product
infecti
viru
data
suggest
assess
transmiss
recoveri
sever
diseas
prioriti
help
control
transmiss
despit
fact
lopinavirritonavir
seem
highli
effect
patient
mani
import
takeaway
studi
investig
appropri
priorit
speed
design
trial
could
rapidli
produc
answer
learn
work
help
inform
design
new
trial
clear
rapidli
initi
highqual
random
clinic
trial
possibl
epidem
condit
even
tri
circumst
prevail
wuhan
result
trial
provid
either
convinc
posit
convinc
neg
find
central
clinic
care
danger
coronaviru
outbreak
continu
disclosur
form
provid
author
avail
full
text
editori
nejmorg
editori
publish
march
nejmorg
